Page 6 - Accelerate Diagnostics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Accelerate Diagnostics Stock (NASDAQ: AXDX) stock price, news, charts, stock research, profile.

Accelerate Diagnostics Inc. (AXDX) reported that its preliminary revenue for the fiscal year 2023 declined to about $12.1 million from last year's $12.8 million, due to a challenging capital sales environment in all sales regions.

TUCSON, Ariz., Jan. 7, 2024 /PRNewswire/ --  Accelerate Diagnostics, Inc. , an in vitro diagnostics company dedicated to providing services that improve patient outcomes and lower healthcare costs...

Equities research analysts at StockNews.com assumed coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX – Get Free Report) in a report released on Thursday. The brokerage set a “hold” rating on the medical research company’s stock. Several other brokerages also recently commented on AXDX. William Blair reiterated an “outperform” rating on shares of Accelerate Diagnostics in […]

Cytovale, a San Francisco-based medical diagnostics company, raised $84 million in Series C funds to advance the commercialization of its diagnostic test for early sepsis detection. Using standard blood draws, the test provides results in under 10 minutes. It is meant to detect sepsis in patients who present to hospital emergency departments.